$ARWR News

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Presents Interim Results From Phase 1/2a Clinical Trial Of ARO-INHBE, Investigational RNAi Therapeutic Developed As Potential Treatment For Obesity And Metabolic Dysfunction-Associated Steatohepatitis

Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Bernstein Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $46

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum

Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived

ARWR: Multiple Important Clinical Readouts in 2H26

Arrowhead (ARWR) Q2 2026 Earnings Transcript

RBC Capital Maintains Outperform on Arrowhead Pharma, Raises Price Target to $87

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals Q2 Earnings Call Highlights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results